McGrath C, Hegarty A M, Hodgson T A, Porter S R
Periodontology & Public Health, Faculty of Dentistry, Prince Philip Dental Hospital, University of Hong Kong, 34 Hospital Road, Hong Kong SAR, China.
Int J Oral Maxillofac Surg. 2003 Jun;32(3):334-6. doi: 10.1054/ijom.2002.0377.
The aim of this study was to evaluate the sensitivity of two patient-centred outcome measures to the topical application of a corticosteroid (betamethasone) in the treatment of oral lichen planus (OLP). Forty-eight patients with clinical and histological features of OLP were recruited to take part in a 6-week study of the effectiveness of topical betamethasone for the treatment of symptomatic OLP. Participants completed a questionnaire incorporating the 16-item UK Oral Health Related Quality Of Life measure (OHQOL) and the 14-item Oral Health Impact Profile (OHIP-14), rated their pain on 'global' and visual analogue scales (VAS) and underwent an oral examination, at the start and end of the trial. Four (8%) patients failed to complete the study. The clinical signs of OLP had improved for half (22) of the patients following treatment. Twenty-nine (66%) reported that their oral pain had reduced ('global' scale). More objectively, there were significant differences in VAS ratings of pain (P =0.005), OHIP-14 scores (P =0.036) and OHQOL scores (P =0.003) between the start and end of the trial. In conclusion, both OHQOL and OHIP-14, patient-centred outcome measures are sensitive to the clinical effects of topical betamethasone in the treatment of oral lichen planus.
本研究旨在评估两种以患者为中心的疗效指标，对于局部应用皮质类固醇（倍他米松）治疗口腔扁平苔藓（OLP）的敏感性。48例具有OLP临床和组织学特征的患者被纳入一项为期6周的研究，以观察局部应用倍他米松治疗有症状OLP的有效性。参与者在试验开始和结束时完成了一份包含16项英国口腔健康相关生活质量量表（OHQOL）和14项口腔健康影响程度量表（OHIP - 14）的问卷，用“整体”和视觉模拟量表（VAS）对疼痛进行评分，并接受口腔检查。4例（8%）患者未完成研究。治疗后，一半（22例）患者的OLP临床体征有所改善。29例（66%）报告称其口腔疼痛减轻（“整体”量表）。更客观地说，试验开始和结束时，疼痛的VAS评分（P = 0.005）、OHIP - 14评分（P = 0.036）和OHQOL评分（P = 0.003）存在显著差异。总之，OHQOL和OHIP - 14这两种以患者为中心的疗效指标，对局部应用倍他米松治疗口腔扁平苔藓的临床效果敏感。
